Gynecologic cancer
PRINCIPAL INVESTIGATORS
- Jordi Ponce I Sebastià
- Marta Gil Martin
- Mireia Martín Satué
- David Llobet Navas
- Ruth Rodriguez Barrueco
- Beatriz Pardo Búrdalo
CLINICAL RESEARCHERS
- Maria Del Mar Varela Rodriguez
- Mª Dolores Martí Cardona
- Marc Barahona Orpinell
POSTDOCTORAL RESEARCHERS
- Susanna Marín i Borràs
- Laura Devis Jauregui
- Carla Trapero Candela
- Laura Coll Iglesias
- Nuria Bonifaci Cano
- Katja Gassner
PREDOCTORAL RESEARCHERS
- Julia Migo Aran
- August Vidal i Bel
- Esther Guerra Fernández
- Eva Soler Sole
- Aintzane Rodriguez Barrante
- Maria Del Rosario Taco Sanchez
SCIENTIFIC SUPPORT
- Francisco Javier Llobet Navàs
- Ricard Bonilla Amadeo
- Axel Rodriguez Vazquez
Cancer
Oncobell
Scientific production
40
PAPERS
Average IF: 7,175
20
LED PAPERS
Average IF: 6,390
9 PUBLICATIONS IN FIRST DECILE
27 PUBLICATIONS IN FIRST QUARTILE
34 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Kim,TW;Bedard,PL;Lorusso,P;Gordon,MS;Bendell,J;Oh,D;Ahn,MJ et al, Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors A Phase 1a/1b Nonrandomized Controlled Trial, JAMA Oncol., 2023;9(11):1574-1582, doi:10.1001/jamaoncol.2023.3867
- Crosas Molist,E;Graziani,V;Maiques,O;Pandya,P;Monger,J;Samain,R;George,SL et al, AMPK is a mechano-metabolic sensor linking cell adhesion and mitochondrial dynamics to Myosin-dependent cell migration., Nat. Commun., 2023;14(1):2740-2740, doi:10.1038/s41467-023-38292-0
- Samain,R;Maiques,O;Monger,J;Lam,H;Candido,J;George,S;Ferrari,N et al, CD73 controls Myosin II-driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells, Sci. Adv., 2023;9(42):doi:10.1126/sciadv.adi0244
- Costas,L;Onieva,I;Pelegrina,B;Marin,F;Carmona,A;López Querol,M;Frias Gomez,J et al, Evaluation of Somatic Mutations in Urine Samples as a Noninvasive Method for the Detection and Molecular Classification of Endometrial Cancer, Clin. Cancer Res., 2023;29(18):3681-3690, doi:10.1158/1078-0432.CCR-23-0367
- Espinosa Sotelo,R;Fuste,NP;Penuelas Haro,I;Alay,A;Pons,G;Almodovar,X;Albaladejo,J et al, Dissecting the role of the NADPH oxidase NOX4 in TGF-beta signaling in hepatocellular carcinoma, Redox Biol., 2023;65102818-102818, doi:10.1016/j.redox.2023.102818
Research highlights
PROJECTS
3 Granted competitive projects
10 Ongoing competitive projects
8 Started clinical trials
48 Ongoing clinical trials
1 Ongoing non competitive project
PUBLISHED WORKS
1 Thesis
3 Clinical guidelines
Selected projects
- 17ACL120. A PHASE IA/B OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARACOKINETICS OF MTIG7192A AS A SINGLE AGENT AND INCOMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS. Genentech, Inc.. Budget: 619.866€. 2017- . PI: Gil Martin, Marta.
- 19ACL209. ESTUDIO DE FASE 1, ABIERTO, MULTICÉNTRICO Y DE VARIOS GRUPOS DE MK-4830 EN MONOTERAPIA Y EN COMBINACIÓN CON PEMBROLIZUMAB EN PARTICIPANTES CON TUMORES SÓLIDOS AVANZADOS. MERCK SHARP & DOHME ESPAÑA S.A. Budget: 521.875€. 2019- . PI: Gil Martin, Marta.
- 19PSJ014. TARGETING THE AUTORESISTOME AS A NEW THERAPEUTIC STRATEGY IN ENDOMETRIAL CANCER. Asociación Española Contra el Cáncer (AECC). Budget: 299.849,22€. 2019-2023. PI: LLOBET NAVAS, DAVID.
- 2023-151-1. ESTUDIO TIPO CESTA DE FASE 1B/2, MULTICÉNTRICO Y ABIERTO QUE EVALÚA LA SEGURIDAD Y EFICACIA DE
BEMARITUZUMAB EN MONOTERAPIA EN TUMORES SÓLIDOS CON SOBREEXPRESIÓN DE FGFR2B (FORTITUDE-301). Amgen, S.A.. Budget: 240.251€. 2023- . PI: Gil Martin, Marta. - 18ACL156. ESTUDIO DE FASE I, ABIERTO, MULTICÉNTRICO, DE BÚSQUEDA DE DOSIS DE TNO155 ORAL EN PACIENTES ADULTOS CON TUMORES SÓLIDOS AVANZADOS. Novartis Farmacéutica, S.A.. Budget: 233.522€. 2018- . PI: Gil Martin, Marta.